Advert - Daiichi-Sankyo – Case AUTH/3542/7/21

• Date posted
  12 December 2022
• Sanction
  Advertisement,
• Case number/s
  AUTH/3542/7/21 - Complainant v Daiichi-Sankyo

For a misleading claim for Nilemdo (bempedoic acid) and Nustendi (bempedoic acid and ezetimibe) which did not clearly state their contraindications with the concomitant use with certain doses of simvastatin (information in this regard was provided in a footnote), was not capable of substantiation and potentially adversely affected patient safety, Daiichi-Sankyo was ruled in breach of the following clauses of the 2021 Code:

Clause 2 - Bringing discredit upon, and reducing confidence in, the pharmaceutical industry

Clause 5.1 - Failing to maintain high standards

Clause 6.1 - Making a misleading claim

Clause 6.2 - Making an unsubstantiated claim